Journal of Cancer Genetics And Biomarkers

Submit Manuscript
About the Journal

About the Journal of Cancer Genetics and Biomarkers

A peer-reviewed, open-access home for the genetics, genomics, and biomarker science of cancer.

The Journal of Cancer Genetics and Biomarkers (JCGB) publishes research on the genetic, genomic, and molecular basis of cancer and on the discovery and validation of cancer biomarkers — from laboratory mechanism to translational and clinical application. Published by Open Access Pub, continuously since 2014.

Our purpose

Connecting molecular mechanism to clinical translation

JCGB exists to connect the molecular understanding of cancer to its clinical translation. The journal publishes work that moves from mechanism — how tumours arise, evolve, and resist treatment — to measurable biomarkers that inform diagnosis, prognosis, and therapy selection.

In doing so, it supports the wider effort to make oncology more precise, more molecularly grounded, and more directly informed by genetic and genomic evidence — giving cancer-genetics and biomarker research a dedicated, permanent, open-access record.

Cancer genetics & genomicsThe somatic and germline basis of malignancy.
Molecular oncologyMechanisms of tumour initiation, progression, and resistance.
Hereditary cancerGermline predisposition and familial risk.
BiomarkersDiagnostic, prognostic, and predictive markers, including liquid-biopsy analytes.
Precision medicine & translationTurning molecular signatures into clinical decisions.
What JCGB publishes

Aims & scope

JCGB publishes original and review scholarship across the genetic, genomic, and biomarker science of cancer — connecting mechanism, discovery, and validation in one place.

MECHANISM

Molecular tumorigenesis

Oncogenic pathway dysregulation, tumour-suppressor loss, genomic instability, and the DNA-damage response.

DISCOVERY

Biomarker discovery & validation

Genomic, transcriptomic, and proteomic signatures for stratification, prognosis, and therapy selection.

LIQUID BIOPSY

ctDNA, CTCs & MRD

Circulating tumour DNA, tumour cells, exosomes, and minimal-residual-disease monitoring.

EVOLUTION

Tumour & clonal dynamics

Clonal architecture, mutational signatures, metastasis, and therapy-induced evolution.

RESISTANCE

Targets & pharmacogenomics

Druggable-target identification, acquired resistance, synthetic lethality, and response genomics.

GERMLINE

Hereditary predisposition

Inherited cancer syndromes, germline variant pathogenicity, and familial-cancer biomarkers.

EPIGENETICS

Cancer epigenetics

DNA methylation, histone and chromatin remodelling, and non-coding-RNA regulation.

MICROENV.

Tumour microenvironment

Immune, stromal, and metabolic interactions shaping progression and treatment response.

MULTI-OMICS

Functional & computational genomics

CRISPR screens, organoid and PDX models, single-cell and spatial multi-omics for precision oncology.

Written forCancer geneticists, molecular oncologists, pathologists, and translational researchers.
Article typesOriginal research, reviews, methods papers, short communications, and editorials.
Strongest fitStudies carrying a clear genetic, genomic, or biomarker dimension linking molecular findings to cancer biology.

Scope clarification

JCGB prioritises studies with a genomic, molecular, or biomarker foundation. Clinical diagnosis, patient management, treatment outcomes, and therapy protocols are considered when they integrate molecular or biomarker analyses, mechanistic insight, or validated translational endpoints. Purely descriptive clinical reports without a genomic, molecular, or biomarker component are outside the journal's scope.

How JCGB works

Editorial standards, peer review & integrity

Editorial standards & peer review

JCGB is guided by an international editorial board and evaluates every submission on scientific merit — the rigour, validity, and contribution of the work. Manuscripts are matched to reviewers with subject expertise relevant to the specific topic under assessment.

Peer-review model: Single-blind (double-blind on request)

Research integrity & ethics

  • Publication ethics — the journal follows COPE-aligned publication ethics.
  • Authorship & competing interests — authors declare contributions and any competing interests.
  • Originality — submissions are screened for plagiarism and must be original and not under consideration elsewhere.
  • Corrections & retractions — errors are addressed through published corrections or retractions.
  • Data availability — authors are expected to make the data underlying their findings available where possible.
  • Use of AI — generative-AI use must be disclosed; AI cannot be an author, and authors remain responsible for their content.
Open science

Open access, copyright & publishing

Open access & copyright

All articles are open access under a Creative Commons Attribution (CC BY) licence — free to read, share, and reuse with attribution, and authors retain copyright of their work.

  • Published under CC BY, authors retain copyright
  • Every article receives a permanent Crossref DOI
  • Free to read and self-archive worldwide
  • Participating in the Portico digital-preservation program
Identifiers & preservation →

Published by Open Access Pub

JCGB is published by Open Access Pub, which provides the journal's publishing platform, DOI registration, hosting, and participation in the Portico digital-preservation program. This lets the editorial board focus on scholarly quality while the publisher maintains the infrastructure that keeps the work discoverable and permanent.

Editorial policies & ethics →
Submit to JCGB

Bring your cancer-genetics research to a journal built for it.

Menu